Cost‐effectiveness of canagliflozin and dapagliflozin for treatment of patients with chronic kidney disease and type 2 diabetes

卡格列净 达帕格列嗪 医学 2型糖尿病 肾脏疾病 重症监护医学 疾病 糖尿病 内科学 内分泌学
作者
Nguyen Bao Ngoc,Shweta Mital,Shawn Bugden,Hai V. Nguyen
出处
期刊:Diabetes, Obesity and Metabolism [Wiley]
卷期号:25 (10): 3030-3039 被引量:19
标识
DOI:10.1111/dom.15201
摘要

AIM: To examine the cost-effectiveness of adding canagliflozin or dapagliflozin to standard of care (SoC) versus SoC alone in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). MATERIALS AND METHODS: We used a Markov microsimulation model to assess the cost-effectiveness of canagliflozin plus SoC (canagliflozin + SoC), dapagliflozin plus SoC (dapagliflozin + SoC) and SoC alone. Analyses were conducted from a healthcare system perspective. Costs were measured in 2021 Canadian dollars (C$), and effectiveness was measured in quality-adjusted life-years (QALYs). RESULTS: Over a patient's lifetime, canagliflozin + SoC and dapagliflozin + SoC yielded cost savings of C$33 460 and C$26 764 and generated 1.38 and 1.44 additional QALYs compared with SoC alone, respectively. While QALY gains with dapagliflozin + SoC were higher than those with canagliflozin + SoC, this strategy was also more costly with the incremental cost-effectiveness ratio exceeding the willingness to pay threshold of C$50 000 per QALY. Dapagliflozin + SoC, however, generated cost savings and QALY gains compared with canagliflozin + SoC over shorter time horizons of 5 or 10 years. CONCLUSIONS: Dapagliflozin + SoC was not cost-effective versus canagliflozin + SoC in patients with CKD and T2D over the lifetime horizon. However, adding canagliflozin or dapagliflozin to SoC was less costly and more effective relative to SoC alone for treatment of CKD and T2D.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
bin_zhang完成签到,获得积分10
1秒前
盏盏发布了新的文献求助10
1秒前
岳志伟完成签到 ,获得积分10
1秒前
怕黑的白玉完成签到,获得积分10
1秒前
2秒前
zzyh完成签到,获得积分10
2秒前
2秒前
2秒前
2秒前
2秒前
3秒前
3秒前
3秒前
3秒前
轩辕十四完成签到,获得积分10
4秒前
斯文败类的应助被Akiba采纳,获得10
4秒前
岳志伟关注了科研通微信公众号
5秒前
斯文败类的应助被Joehq_1203采纳,获得10
5秒前
6秒前
6秒前
6秒前
6秒前
Nole的应助被今天没有哭鸭采纳,获得10
6秒前
Maestro_S的应助被shaco采纳,获得10
6秒前
lili完成签到,获得积分10
6秒前
脑洞疼的应助被15331970326采纳,获得10
7秒前
无极微光的应助被zhoudongxue采纳,获得20
7秒前
8秒前
朱晖发布了新的文献求助20
8秒前
今夜略闲发布了新的文献求助10
8秒前
8秒前
喔喔佳佳L发布了新的文献求助20
8秒前
入司的应助被李麟采纳,获得10
8秒前
Akim的应助被刘泽楷采纳,获得10
9秒前
英姑的应助被楠楠采纳,获得10
9秒前
9秒前
orixero的应助被annona采纳,获得30
9秒前
9秒前
10秒前
瘦瘦大米发布了新的文献求助10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188210
求助须知:如何正确求助?哪些是违规求助? 9576001
关于积分的说明 21844898
捐赠科研通 7786081
什么是DOI,文献DOI怎么找? 3435220
关于科研通互助平台的介绍 2559559
邀请新用户注册赠送积分活动 2482139